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Abstract 
Background: Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike 
the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular death and 
risk factors, aside from lowering plasma glucose levels. With this study we aim at determining whether the treat-
ment with empagliflozin is associated with an improvement in LV functions in diabetic patients with asymptomatic 
LV dysfunction against Sitagliptin, which is presumably neutral on myocardial function. To determine changes in LV 
systolic and diastolic functions we will use speckle-tracking echocardiography, a novel sensitive, non-invasive, bedside 
method allowing the calculation of LV global longitudinal strain (GLS), an index of myocardial deformability, as well as 
3D echocardiography, which allows a better evaluation of LV volumes and mass.
Methods: The EMPA-HEART trial will be a phase III, open label, active-controlled, parallel groups, single centre, 
exploratory study conducted in Pisa, Italy. A cohort of 75 diabetic patients with normal LV systolic (2D-Echo EF > 50%) 
and renal (eGFR sec MDRD > 60 ml/min/1.73 mq) functions and no evidence of valvular and/or ischemic heart disease 
will be randomized to either Empagliflozin 10 mg/die or Sitagliptin 100 mg/die. The primary outcome is to detect a 
change in GLS from baseline to 1 and 6 months after treatment initiation. The secondary outcomes include changes 
from baseline to 6 months in 3-D Echocardiography EF, left atrial volume and E/E′,  VO2max as measured at cardio-
pulmonary test, cardiac autonomic function tests (R–R interval during Valsalva manoeuvre, deep-breathing, lying-to-
standing), and the determination of a set of plasma biomarkers aimed at studying volume, inflammation, oxidative 
stress, matrix remodelling, myocyte strain and injury.
Discussion: SGLT2 inhibitors might affect myocardial functions through mechanisms acting both directly and indi-
rectly on the myocardium. The set of instrumental and biohumoral tests of our study might actually detect the pres-
ence and entity of empagliflozin beneficial effects on the myocardium and shed light on the mechanisms involved. 
Further, this study might eventually provide information to design a clinical strategy, based on echocardiography and/
or biomarkers, to select the patients who might benefit more from this intervention.
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Background
Diabetes mellitus and myocardial dysfunction
The pathogenesis of myocardial dysfunction in type 2 
diabetes mellitus (T2D) is multifactorial, being the dia-
betic myocardium chronically exposed to a mixture of 
metabolic, haemodynamic, macro and microvascular 
insults, which altogether are responsible for the greater 
incidence of heart failure (HF) and cardiovascular death 
of these patients [1]. The peculiar complex and multi-
factorial pathogenesis of HF in T2D patients fit into a 
disease-specific condition named diabetic cardiomyo-
pathy, which may be found in isolation or associated to 
coronary artery and/or hypertensive heart disease [2, 3]. 
In this scenario, is not surprising that asymptomatic left 
ventricular (LV) dysfunction, defined as either systolic or 
diastolic abnormalities in the absence of clinically detect-
able cardiac disease, is highly prevalent in T2D patients, 
with estimates ranging from 50 to 70% [4, 5]. A better 
knowledge of its early-stage risk factors and its natural 
evolution would allow the design of effective prevention 
strategies as strongly recommended by current clini-
cal guidelines, which emphasize the importance of early 
diagnosis and interventions in subjects at risk [3]. How-
ever, one major limitation to this approach is the lack 
of consensus with regard to the best method to detect 
asymptomatic LV dysfunction, which is responsible for 
the limited information, particularly about the effects 
of antidiabetic drugs on LV performance. The available 
methods for accurately measuring cardiac functions are 
either too complex (cardiac magnetic resonance) or not 
sensitive enough (brain-derived natriuretic peptide—
BNP-, 2D ejection fraction—EF- and tissue Doppler) to 
detect subtle changes in cardiac performances, particu-
larly in asymptomatic subjects.
Sodium‑glucose linked co‑transporter 2 (SGLT2) inhibitors 
in cardiovascular disease
In the kidney, plasma glucose is freely filtered into the 
urine through the glomerulus and is reabsorbed in the 
tubule through an efficient system of ATP-dependent 
transporter proteins, the sodium-glucose-linked co-
transporters (SGLT). SGLTs are found in the proximal 
tubule in two different isoforms, namely SGLT1 and 
SGLT2. Both proteins bind and transport sodium and 
glucose, SGLT2 in a one-to-one and SGLT1 in a two-to-
one ratio, while showing some clinically relevant differ-
ences. SGLT2, a high-capacity, low-affinity transporter, is 
present in segment 1 of the tubule and normally accounts 
for almost 90% of the entire kidney glucose reuptake. In 
T2D, secondary to chronic hyperglycemia, the expres-
sion of SGLT2 is upregulated, leading to an increased 
renal tubular reabsorption exacerbating hyperglycemia 
[6]. Conversely, SGLT1 is a low-capacity, high-affinity 
transporter present in segment 3 of proximal tubule, 
but that is also expressed, to a greater extent than in the 
kidney, in the small intestine and in the heart [7]. In the 
latter, SGLT1 is thought to be localized both in cardiomy-
ocytes and in capillaries [8]. Besides their proven efficacy 
in lowering plasma glucose levels, SGLT2 inhibitors have 
also been shown to have potential benefits for improv-
ing other cardiovascular risk factors, such as body weight 
and blood pressure, while being well tolerated [9]. The 
study EMPA-REG, quite unexpectedly, reported in the 
diabetic population a 35% reduction in hospitalization for 
HF and a 32% reduction in cardiovascular death largely 
due (data from the Supplementary appendix of ref [10]) 
to a reduction in fatal events related either to worsening 
of HF (incidence rates: 0.2 vs 0.8%) or to sudden death 
(incidence rates: 1.1 vs 1.6%, in the pooled empagliflozin 
and placebo group, respectively), while outcomes more 
closely related to atherosclerosis, e.g. cerebrovascular and 
ischemic heart diseases, were only marginally affected. In 
addition, the benefit was evident very early after treat-
ment initiation (~ 6 months). Since other oral hypoglyce-
mic drugs have been shown either to increase the risk of 
HF [11, 12], or to be neutral [13, 14], then the hypothesis 
that empagliflozin might directly and rapidly improve LV 
function, irrespective of the improvement in metabolic 
control, has been raised. Similar results on HF have been 
recently reported with another SGLT2 inhibitor, canagli-
flozin, in the recently published CANVAS study [15] and 
also in a large observational study on users of SGLT-2 
inhibitors (CVD-REAL) in which the majority of the sub-
jects were treated with dapagliflozin [16]. Diastolic func-
tion in ob/ob in a preliminary report in 10 patients of 
EMPA-HEART study short-term (151 days) with empa-
gliflozin was associated with a 15% reduction in LV mass 
index and a 13% increase in early lateral annular tissue 
Doppler velocity (e′), a proxy of LV compliance. Finally, 
the recent article by Januzzi et  al. [17] demonstrated 
that chronic therapy with Canagliflozin is associated 
with delayed physiologic rise in serum NT-proBNP and 
high sensitive troponin I (hsTnI)  in a 2  years’-follow up 
in older T2D patients by a little but significative amount, 
thus suggesting a beneficial role. Despite this, informa-
tion with respect to SGLT2 inhibitors effect on myocar-
dial function is very limited.
Speckle‑tracking and 3D echocardiography for early 
detection of myocardial dysfunction
A recent sensitive, non-invasive and bedside method 
for the evaluation of myocardial systolic and diastolic 
function, namely 2D-speckle-tracking echocardiography 
(STE), has recently been developed and validated (against 
tissue Doppler, cardiac magnetic resonance and sonomi-
crometry) in large cohorts of patients, including subjects 
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with T2D [18–21]. STE exploits the natural acoustic 
markers that are evident in grey-scale ultrasound images 
within the myocardial tissue, which corresponds to spe-
cific anatomical structures [22]. The spatial displace-
ment of the speckles during the cardiac cycle reflects 
the strain of the myocardium and can be tracked on a 
frame-by-frame basis for each region of interest both in 
longitudinal and radial directions according the standard 
echocardiographic approaches. Strain values are calcu-
lated for each standard myocardial segment (segmental 
strain) and the average value of all segmental strains pro-
vides the global LV strain.
Currently only LV global longitudinal strain (GLS) has 
been validated. Interestingly, among T2D outpatients 
without valvular disease, previous cardiac events or 
symptoms, and with a normal 2D EF, an abnormal GLS 
measured by STE has been consistently found in 30–50% 
of the subjects [23–25]. Of note, in T2D patients the con-
dition of normal EF and abnormal GLS was associated 
with a reduced  VO2max at cardiopulmonary test [20], 
and, most importantly, to an adverse cardiovascular out-
come at 10-year follow-up [26].
Very recently, 3D echocardiography has also become 
available for clinical use. Combined matrix array trans-
ductors allow contemporary and real-time bedside 
evaluation of 2D and 3D images. Being more accurate 
with respect to 2D echography, which relies on a set of 
approximate geometric assumptions, it currently rep-
resents a promising tool in the measurement of both 
systolic and diastolic volumes, as well as  LV mass and 
remodeling itself [27].
Biomarkers of cardiac function and mechanisms of disease
In order to detect subclinical LV dysfunction and to 
provide information on the mechanisms potentially 
implicated in the diabetic cardiac dysfunctions, we have 
chosen a set of plasma biomarkers, which not only look 
at specific pathways (volume, inflammation, oxidative 
stress, matrix remodelling, myocyte strain and injury) 
but were also validated against hard endpoints [28].
Volume biomarkers and total body water (TBW)
We will measure plasma aldosterone (DiaSorin, Salug-
gia, Italy; intra-assay 9.7% and inter-assay 11.5%, n.v. 
3.5–30.0  ng/dl) and renin (CisBIO, Bedford, MA, USA; 
intra-assay 1.8% and interassay 4.0%, n.v. 5.1–59.4  pg/
ml) as a proxy for rennin-angiotensin-aldosterone sys-
tem (RAAS) activation, which track effective circulat-
ing volume. The activation of the RAAS system also has 
been shown to be a prognostic marker in patients with 
HF. In a cohort of 996 subjects [29] plasma renin has 
been shown to predict death at 3 years follow-up, inde-
pendently of the most important predictors: age, EF and 
NT-pro-BNP. The body fluid status will be assessed also 
by measuring total body water (TBW) using the deuter-
ated water dilution method [30]. A fixed amount (10 g) of 
99% deuterated water (Sigma Aldrich) will be ingested at 
10:00 p.m. and the patient will collect a urine sample the 
subsequent morning at 7:00. TBW will be calculated as 
the deuterium dilution space divided by 1.04, to correct 
for exchange of the deuterium label with non-aqueous H 
of body chemicals [31]. Isotope abundances in urine were 
determined in duplicate by nuclear magnetic resonance 
(2H NMR) according to the protocol described by Khaled 
et al. [32].
Myocardial parietal stress biomarkers
We will measure natriuretic peptides (NPs); namely brain 
natriuretic peptide (BNP) and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) that are released into 
the bloodstream in direct proportion to the mechani-
cal stress of the myocardium [33]. As such, NPs have 
been proved useful in screening asymptomatic subjects 
at risk of developing HF, such as the elderly and those 
with hypertension, diabetes, or asymptomatic coronary 
artery disease [33, 34], and will be used in this study for 
grading and monitoring the changes in asymptomatic 
LV dysfunctions observed with STE. More recently also 
proadrenomedullin has been validated as a myocardial 
parietal stress plasma biomarker. This cardiomyocyte-
derived peptide is released in proportion to cardiac pres-
sure and volume [35] and its serum levels are useful for 
grading HF severity and predict death, either alone or 
when combined with NT-proBNP [36].
Cardiomyocyte injury biomarkers
Plasma troponin-T will be measured to assess cardiomy-
ocyte injury being present in HF patients not only as a 
result of ischemia, but also as a consequence of inflam-
mation, oxidative stress, and neurohormonal activation. 
In fact, with the high-sensitive assay, abnormal tro-
ponin levels can be detected in up to 92% of HF patients, 
wherein are of high prognostic value being associated 
with an increased risk of death even after adjustment for 
baseline variables and BNP [37].
Inflammation/oxidative stress biomarkers
High-sensitivity C-reactive protein (hsCRP) is an acute-
phase reactant synthesized by hepatocytes in response to 
the proinflammatory cytokine interleukin-6 (IL-6) [38] 
in a variety of inflammatory processes. Its serum levels 
appear to be positively associated with HF severity and 
progression being an independent predictor of adverse 
outcomes in patients with acute or chronic HF [39, 
40]. Further, notwithstanding its non-specificity, CRP 
might have a causal role in vascular and/or myocardial 
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damage, since it exerts direct adverse effects on the vas-
cular endothelium by reducing nitric-oxide release and 
increasing endothelin-1 production, as well as by induc-
ing expression of endothelial adhesion molecules [41]. 
Also tumor necrosis factor-alpha (TNF-α) has been pro-
posed as a marker of HF and asymptomatic LV dysfunc-
tion. This pro-inflammatory cytokine has been observed 
to cause LV dilatation, seemingly by activating matrix 
metalloproteinases [42]. Despite the fact that the block-
ade of TNF-α did not result in clinical benefit in patients 
with HF [43], TNF-α levels have been then proposed to 
predict the future development of HF in asymptomatic 
elderly subjects [44]. Together with inflammation, also 
oxidative stress plays a role in determining myocardial 
damage. Since reactive oxygen species are many and are 
difficult to measure we focused on the plasma biomark-
ers that have been validated in clinical trials: myeloper-
oxidase (MPO). The levels of plasma MPO, in fact, are 
elevated in coronary artery disease, possibly having a 
role in determining and revealing LV remodeling [45]. 
Moreover, its levels correlate with the severity of HF and 
are independent predictors of death from HF, even after 
adjustment for baseline variables [46].
Matrix remodelling biomarkers
Being adverse myocardial remodelling largely depend-
ent from excessive collagen synthesis and associated with 
impaired LV function and adverse clinical outcomes in 
patients with HF, we decided to measure type III pro-col-
lagen, whose serum level has been shown to be an inde-
pendent predictor of adverse outcomes in patients with 
HF [47].
Methods
Rationale and aim of the study
The specific medical need addressed by this study is 
to offer T2D patients, who appear to be at high risk for 
developing HF and its lethal consequences, a new thera-
peutic option capable not only of controlling their plasma 
glucose but also improving their underlying subclini-
cal cardiomyopathy. Further, this study might eventually 
provide information to design a clinical strategy, based 
on echocardiography and/or biomarkers, to select the 
patients who might benefit more from this intervention.
With this study we aim at verifying whether, in T2D 
patients with subclinical cardiomyopathy (i.e. without: 
overt HF symptoms and signs, significant valvular heart 
disease, evidence of inducible myocardial ischemia and 
with 2-D ejection fraction ≥  50%) the treatment with 
empagliflozin is associated with an improvement in LV 
systolic function, as measured by GLS through STE, in 
comparison to sitagliptin, an equally effective plasma 
glucose lowering agent, which has been shown to be neu-
tral on HF-related events prevention.
Study design
The EMPA-HEART trial will be a phase III, open label, 
active-controlled, parallel groups, single centre, explora-
tory study conducted in Pisa, Italy (Fig. 1). This is a proof-
of-concept study aiming at evaluating whether the chronic 
treatment with the SGLT-2 inhibitor empagliflozin has an 
effect on myocardial function above and beyond its effect 
on metabolic control. The patients will be randomized to 
either empagliflozin 10  mg/die or to Sitagliptin 100  mg/
die as an active comparator, which has a similar potency 
in terms of glucose control and, on the bases of large clini-
cal trials, does not influence the risk of developing HF. 
The study consists of 7 visits (see  Table  1) and  will last 
2  years, therefore, being the start programmed for July 
2017 the end of the study is expected for July 2019.
Study population
Volunteers will be recruited among patients attend-
ing visits at the Diabetes Outpatient Unit of Internal 
Medicine at the Pisa University Hospital (AOUP). The 
experimental sessions will take place in the Laboratory of 
Nutrition, Metabolism and Atherosclerosis and part in the 
unit of Cardio-angiology of the AOUP under the respon-
sibility of AN and VD, respectively. All potential partici-
pants who meet the following criteria will be eligible for 
the trial:
Inclusion criteria
  • Male or female affected by type 2 diabetes mellitus 
(T2D).
  • Age ≥ 40 and ≤ 80 years.
  • HbA1c levels ≥ 53 (7%) and ≤ 69 mmol/mol (8.5%).
  • On stable (since 3 months) antidiabetic therapy with 
either Metformin alone or Metformin + basal insulin 
(this constraint is determined by the present Italian 
prescription rules).
  • On stable (since 3  months) cardio-active therapies 
(e.g. anti-hypertensive drugs, diuretics, drugs for 
asthma or migraine prophylaxis).
  • Preserved kidney function as defined by 
eGFR ≥ 45 ml min−1 1.73 m2.
  • Preserved left ventricular function as defined by 
EF ≥ 50%.
Exclusion criteria
  • Refuse or inability to give informed consent.
  • Patients unlikely to comply with the protocol or una-
ble to understand the nature, scope and possible con-
sequences of the study.
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  • Employees of the investigator or study centre (i.e. 
principal investigator, sub-investigator, study coordi-
nators, other study staff, employees, or contractors of 
each), with direct involvement in the proposed study 
or other studies under the direction of that investiga-
tor and/or study centre, as well as family members of 
the employees or the investigator.
  • Patients with type 1 diabetes mellitus.
  • Pregnancy or active breast feeding.
  • History of hospitalization for acute coronary syn-
drome or heart failure.
  • Respiratory insufficiency or history of clinically sig-
nificant respiratory diseases (chronic obstructive pul-
monary disease).
Fig. 1 Study design flowchart. EF ejection fraction, GLS global longitudinal strain, HbA1c glycated haemoglobin, LA left atrium, TBW total body water, 
VO2max  O2 consuption at peak of stress
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  • NYHA class III and IV or other symptoms of heart 
failure (breathlessness, orthopnoea, paroxysmal noc-
turnal dyspnoea, fatigue, increased time to recover 
after exercise, ankle swelling) unrelated to most com-
mon non-cardiac causes.
Signs of heart failure (elevated jugular venous pressure, 
third heart sound, laterally displaced apical impulse).
  • Acute or chronic inflammatory diseases.
  • History of active neoplastic disease within the last 
5 years.
  • Patients with known hypersensitivity to empagliflo-
zin and its excipients.
  • Volume-depleted patients or those who, in the judge-
ment of the investigator, may be at risk for dehydra-
tion (abuse of diuretics or laxatives, chronic diar-
rhoea etc.).
  • History of recurrent or serious genitor-urinary infec-
tions.
  • Patients with known hypersensitivity to sitagliptin 
and its excipients.
  • History of acute or chronic pancreatic disease.
  • Patients who received any investigational new drug 
within the last 12 weeks.
  • Severe obesity (body mass index, BMI ≥ 40 kg/m2).
  • Uncontrolled blood pressure, defined as 
> 160/100 mmHg.
  • Expected glomerular filtration rate (eGFR) < 45 ml/
min/1.73 m2.
  • Severe hepatic insufficiency and/or significant abnor-
mal liver function defined as aspartate aminotrans-
ferase (AST) > 3× upper limit of normal (ULN) and/
or alanine aminotransferase (ALT)  >  3× ULN or 
total bilirubin > 2.0 mg/dl.
  • Cardiac arrhythmia (2nd grade AV block, atrial fibril-
lation, pacemaker, high incidence premature beats).
  • Clinically relevant cardiac valvular disease.
  • Ejection fraction <  50% or presence of regional left 
ventricular contraction impairment.
  • Poor acoustic window or poor quality of echocardio-
graphic imaging.
  • Inability to perform the cardiopulmonary exercise 
test.
  • Evidence of inducible myocardial ischemia at the car-
diopulmonary test.
Randomisation and treatment allocation
Patients will be randomized to a 26-week treatment with 
either empagliflozin 10  mg or sitagliptin 100  mg/daily 
as add-on to the background therapy. This will be done 
with a randomization matrix of 75 numbers calculated 
using the web-based service at http://www.random.org, 
assigning pair and even numbers to empagliflozin and 
sitagliptin, respectively. If the patient requires additional 
treatment for the presence of hyperglycemia, either 
symptomatic or detected at self-glucose monitoring (fast-
ing plasma glucose (≥  10  mM), the following measures 
will be sequentially taken: (a) lifestyle measures rein-
forcement, (b) initiation or up titration of metformin, (c) 
Table 1 Study conduction flowchart overview of all visit and tests scheduled for participants of the EMPA-HEART trial
Visits Screening Run‑in Baseline Entry 1 Month 6 Months Study end
Time (week) − 5 − 3 − 1 0 4 24 26
Medical history X X
Physical examination X X X X
ECG X X
Preliminary I/E criteria X





Body water assessment X X
Safety sample X X
Drug compliance X
Adverse effect X X
Cardiac autonomic tests X X
Exercise test X X
Echocardiography X X X
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To verify whether, in our population of T2D patients with 
normal 2-D EF (≥ 50%) and without evidence of cardiac 
valvular or ischemic disease, the chronic treatment with 
empagliflozin is associated with an improvement in LV 
systolic function as measured by GLS through STE in 
comparison to sitagliptin, an equally effective plasma 
glucose lowering agent presumably neutral on cardiac 
function.
Secondary objectives
1. To compare the effects of the 2 treatments on:
• 3D echo left ventricular systolic and diastolic func-
tional parameters
•  Plasma mechanism-oriented biomarkers
•  VO2max
•  Cardiac autonomic function tests.
2. To test whether the effect of empagliflozin differs 
in the subgroup of patients with more pronounced 
abnormalities in cardiac systolic function at baseline 
(GLS > − 18%).
3. To assess in the whole cohort the relationship 
between the changes in cardiac function indices 
(GLS or 3D) and the concomitant changes in car-
diac biomarkers and/or in blood pressure, weight and 




Changes in global longitudinal strain (GLS) from baseline 
to 1 and 6 months after treatment initiation.
Secondary outcome variables
Changes from baseline at 6 months after treatment initia-
tion in
1. 3-D Echocardiography EF, left atrial volume and E/E′.
2. VO2max, as measured at cardiopulmonary test.
3. Myocardial parietal stress plasma biomarkers (BNP, 
NT-proBNP, proadrenomedullin), inflammation/oxi-
dative stress plasma biomarkers (hsCRP, TNF-alpha, 
mieloperoxidase, uric acid) and cardiac remodel-
ling/cytolysis biomarkers (type III pro-collagen, tro-
ponine), body volume biomarkers (total body water, 
plasma renin and aldosterone).
4. Cardiac autonomic function tests (R–R interval dur-
ing Valsalva manoeuvre, deep-breathing, lying-to-
standing).
Exploratory pre‑defined hypothesis‑driven analyses
1. Whether changes from baseline at 6  months after 
treatment initiation in plasma markers of volume 
control (plasma aldosterone-to-renin ratio and 
total body water), cardiomyocyte strain (BNP, NT-
proBNP, proadrenomedullin), inflammation/oxida-
tive stress (hsCRP, TNF-α, myeloperoxydase, uric 
acid), matrix remodeling (procollagen type III) and 
myocyte injury (Troponin T) help understanding the 
mechanisms of action through which the treatments 
exert their effect/s on the heart.
2. Whether changes from baseline at 6  months after 
treatment initiation in cardiac autonomic function 
score (based on RR changes with Valsalva, deep 
breathing, standing-to-laying) contribute to the 
mechanisms of action of the treatments.
3. Whether the effects of the treatments differ in the 
subgroup of patients whom at baseline have mild 
abnormalities in cardiac systolic function or abnor-
mal values of plasma biomarkers or abnormal cardiac 
autonomic function tests [lower 50 percentile of GLS, 
atrial enlargement (LAVI  >  34  ml/m2), LV hyper-
trophy (LVMI > 115 or 90 g/m2, males and females, 
respectively), diastolic dysfunction (E/e′  ≥  13) and 
myocardial strain (Nt-pro-BNP > 125 pg/ml)].
4. Whether the changes in cardiac function are depend-
ent on the concomitant changes in blood pressure, 
body weight and/or the improvement of the meta-
bolic control and/or fasting plasma ß-OH butirrate 
concentration.
Power calculation and sample size
The size of a change in GLS that is considered clinical 
relevant is based on the following data: (a) mean GLS 
(± SD) as assessed in a population of 114 type 2 diabetic 
subjects without evidence of cardiac disease and with 
2D-EF ≥ 55% according to (15) was: − 19 (± 3) %; (b) a 
difference in GLS of 2.5% (− 21.2 ± 2.7 vs − 18.7 ± 2.8%) 
was observed between stage A and stage B heart failure in 
non-diabetic patients [20], and (c) a similar difference is 
present between subjects with and without diabetes [48]. 
A difference ≥ 2.5% is therefore considered highly clini-
cally meaningful. Given the nature of the study (within 
subject repeated measures) a difference  ≥  1.5% would 
be considered relevant from a pathophysiologic point 
of view. Alpha error is always kept at 0.05. Estimation 
of the SD of the difference is based on an observational 
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study performed in 112 type 2 diabetic patients with 
normal EF in whom after 2 years the GLS changed from 
− 19.7 ± 4.0 to − 18.9 ± 3.8% a difference of 0.8%, which 
was statistically significant (p < 0.001) at a paired t-test. 
The SD of the difference in GLS is not reported, however 
it can be estimated using a web-based engine (http://
www.biomath.info/power/prt.htm) on the bases of the 
available mean and SD and by attributing a value to the 
correlation between the two repeated measurements 
of 0.80 on the bases of the intra observed error in GLS 
measurement 0.7 ± 0.4% according to Kosmala et al. [20] 
and on personal data. This data allowed the SD to be esti-
mated as 2.5%.
Therefore, to detect an absolute  ≥  2.5% difference 
in GLS, a sample size of 30 subjects is required per 
arm. Considering a 21% drop-out, sample size will be 
75 recruited subjects, to have 60 completed. In terms 
of Power for a total sample size of 60 (2 groups of 30), 
given the above-mentioned figures in a paired design 
(either t-test or Wilcoxon) within each of the two treat-
ment groups (n  =  30) the power to detect a differ-
ence of 2.5 and 1.7% is 0.99 and 0.95, respectively. In an 
MANOVA design for three repeated measures (baseline, 
1, 6 months) the power of the study to detect a difference 
between the treatments of 2.5 or 1.7% is 0.98 and 0.80, 
respectively. In an ANCOVA design with 4 covariates 
a sample size of 60 subjects will have the power of 0.71 
to detect an effect of 0.10 (expressed as of proportion of 
variance explained by the effect under consideration), 
which is commonly considered small in biostatistics and 
a power of 0.99 to detect a medium effect (0.25). The 
analysis will be 2-sided, PPS, no interim. 
Discussion
With this study we aim at demonstrating whether the 
treatment with empagliflozin is associated with the 
reversal of the earliest signs of diabetic systolic and dias-
tolic dysfunctions, and at shedding light on the underly-
ing mechanism/s involved (Fig. 2).
The reasons for concentrating on the earliest stages 
of HF stems from the common idea that this condition 
is more susceptible to reversal and also from the data 
of the EMPAREG OUTCOME trial showing the more 
robust effects, both in terms of hospitalization for HF 
Fig. 2 Potential mechanisms implicated in empagliflozin’s beneficial effects on the myocardium (on the left) and the biohuoral/instrumental tests 
performed to highlight them (on the right of the figure). The red vertical arrows indicate an increment, the blue vertical ones indicate a decrement. 
cyt cytoplasm, GLS global longitudinal strain, hsCRP high-sensitive C-reactive protein, KB ketone bodies, m mitochondrion, TBW total body water, 
TNF-α tumor necrosis factor-alpha, VO2max  O2 consuption at peak of stress
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and cardiovascular death, in the patients without HF at 
baseline or diagnosed during the study [10]. We there-
fore focused on patients with normal EF without current 
or prior symptoms of overt HF, but at high risk for the 
condition for presence of T2D and allowing for arterial 
hypertension and structural (LV hypertrophy) or func-
tional (diastolic dysfunction) or biochemical (NT-pro-
BNP) evidence of initial myocardial disease (Stage A 
and B HF according to ACC/AHA guidelines). In terms 
of pathophysiological changes the data are essentially 
based on few experimental studies and speculations [49]. 
SGLT2 inhibitors might actually affect myocardial func-
tions through mechanisms that can act both directly and 
indirectly on the myocardium. Chronic treatment with 
SGLT2 inhibitors has been associated to a small blood 
pressure reduction (3–4  mmHg mean blood pressure) 
also confirmed by 24-h blood pressure monitoring [50], 
which was not associated to an increase in heart rate [51] 
and was independent of the number and type of base-
line anti-hypertensive drugs [52]. The reasons for this 
blood pressure reduction, though not fully understood, 
is likely to involve the small (5%) weight reduction and 
the minor diuretic and natriuretic effects [50, 51] that are 
induced by glycosuria. Given the size of these changes, 
however, it is unlikely that they entirely justify the clinical 
outcomes. Since SGLT2 inhibitors reduce arterial blood 
pressure without a compensatory increase in heart rate, 
a reduction in the sympathetic tone [53] has also been 
suggested as a potential mechanism. Owing to its renal 
and hemodynamic effects, also other neurohormonal 
axes might be involved, particularly the RAAS and NPs, 
resulting in a change in TBW. To date, however, at the 
best of our knowledge no data is available. With regard 
to body fluid control the information is limited to a sin-
gle preliminary study in which chronic treatment with 
dapagliflozin resulted in a 5% reduction in plasma vol-
ume [50]. A direct vascular effect might also contribute 
to blood pressure changes. Interestingly, a 8-week empa-
gliflozin treatment reduced arterial stiffness in patients 
with type 1 diabetes [54]. Preliminary experimental data 
suggest that SGLT2 inhibitors may improve the vascular 
structural properties, interfering with collagen, elastin, 
advanced glycation end-products [55]. Moreover, the 
SGLT2 inhibitors-induced increased ketone bodies has 
been proposed to facilitate myocardial energetics [56]. In 
fact, myocardial utilization of β-OH-butirrate results in 
a significant increase in ATP production with respect to 
glucose and fatty acid oxidation and in an improved effi-
ciency (hydraulic work/energy from  O2 consumed) in a 
model of isolated working heart by 25% [57].
Together with the above-mentioned indirect effects, 
empagliflozin shows some direct myocardial effects 
as well. In cardiomyocytes, mitochondrial  Ca2+ is 
considered to be one major activator of ATP synthesis 
and of the antioxidant enzymatic network [58]. Elevated 
cardiac cytoplasmic  Na+ and  Ca2+ concentrations and 
decreased mitochondrial  Ca2+ concentration are charac-
teristic hyperglycemia-induced drivers of HF and cardiac 
death. In a recent paper [59] empagliflozin was demon-
strated to reduce cardiomyocytes cardiac cytoplasmic 
 Na+ and  Ca2+ concentrations and to increase mitochon-
drial  Ca2+ levels by directly inhibiting  Na+/H+ exchanger 
(NHE). Previous studies have demonstrated that chronic 
inhibition of NHE prevents or mitigates HF in animal 
models [60], and this might be one of the mechanisms 
through which empagliflozin protects from HF deaths 
and hospitalizations. Finally, recent observation raised 
the possibility that SGLT2 inhibitor treatment might 
also have a beneficial effect on cardiac remodeling. In a 
rat model of progressive HF, it has been observed that 
SGLT2 inhibition could attenuate the increase in LV mass 
and LV end-diastolic diameter [61]. In obese T2D (db/db) 
mice, a 10  week-long treatment with empagliflozin has 
been observed to reduce interstitial cardiac fibrosis, peri-
coronary arterial fibrosis, coronary arterial thickening, 
cardiac interstitial macrophage infiltration, and cardiac 
superoxide levels [62]. In the same study, empagliflozin 
also ameliorated endothelial dysfunction. Moreover, in 
animal models, SGLT-2 inhibitors have been shown to 
reduce myocardial leukocytosis induced by hyperglyce-
mia [63] and to reduce inflammation and oxidative stress 
[64] as well as possibly fibrosis [65]. The only study that 
is available on cardiac function is a preliminary obser-
vation done in 10 T2D patients by using standard 2D 
echocardiography, that reported a small improvement 
in LV mass (reverse remodeling) and diastolic function 
after 5 months of treatment with empagliflozin [21]. To 
date, no data on the effect of SGLT2 inhibitors on car-
diac remodeling in subjects with HF is available, but the 
REFORM trial [66] is currently underway in order to 
investigate, in patients with T2D and HF, the effects of 
dapagliflozin on LV remodeling through cardiac mag-
netic resonance and cardiopulmonary stress test.
Limitations
Despite the estimate high power of the study, this is an 
open, short-term, and relatively small trial. In order to 
prevent any influence of the researcher expectations 
(type 1 error) we will take care that the cardiologist per-
forming the primary and several of the secondary out-
come variables measurements are blind with respect to 
the treatment allocation. In addition, given the expected 
mild degree of systolic dysfunction at baseline caused by 
our strict selection criteria we are somehow protected 
from type 1 error although the risk to occur in a type 2 
error is increased. However, by measuring a full set of 
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other relevant myocardial function parameters and bio-
markers we will actually be able to generate solid data-
driven hypotheses for future studies. The recent evidence 
of the PROLOGUE trial (Yamada), showing that sitag-
liptin is able to prevent the time-related deterioration 
of diastolic function, raises the possibility that our com-
parator is not completely neutral on cardiac function. 
However, this effect was evident after 12, but not after 
6  months of treatment and sitagliptin has been shown 
to be neutral on systolic function in patients with post-
ischemic heart failure with mildly reduced ejection frac-
tion [67]. Therefore, there will be, if any, a small risk of 
type 2 error, which we consider acceptable and eventually 
would, in case, reinforce any observed positive outcome 
of empagliflozin.
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